Formosa Laboratories Inc
TWSE:4746
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
70
117
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Formosa Laboratories Inc
Formosa Laboratories Inc
Current Portion of Long-Term Debt
Formosa Laboratories Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Current Portion of Long-Term Debt
NT$445.1m
|
CAGR 3-Years
18%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Current Portion of Long-Term Debt
NT$113.2m
|
CAGR 3-Years
52%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Current Portion of Long-Term Debt
NT$18.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Current Portion of Long-Term Debt
NT$234.8m
|
CAGR 3-Years
422%
|
CAGR 5-Years
167%
|
CAGR 10-Years
N/A
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Current Portion of Long-Term Debt
NT$2.4B
|
CAGR 3-Years
41%
|
CAGR 5-Years
55%
|
CAGR 10-Years
39%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Current Portion of Long-Term Debt
NT$83.2m
|
CAGR 3-Years
65%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-4%
|
|
Formosa Laboratories Inc
Glance View
Formosa Laboratories, Inc. engages in the research and development of biotechnology new drugs. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2009-11-27. The firm primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The firm distributes its products to Europe, the Americas, Asia and other markets.
See Also
What is Formosa Laboratories Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
445.1m
TWD
Based on the financial report for Sep 30, 2024, Formosa Laboratories Inc's Current Portion of Long-Term Debt amounts to 445.1m TWD.
What is Formosa Laboratories Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
4%
Over the last year, the Current Portion of Long-Term Debt growth was -3%. The average annual Current Portion of Long-Term Debt growth rates for Formosa Laboratories Inc have been 18% over the past three years , 3% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet